Minimally invasive mitral valve repair: Ten-year outcomes of the “Re-Lock technique” for complex bileaflet mitral valve disease

The objective was to evaluate the 10-year clinical and echocardiographic outcomes of minimally invasive Re-Lock mitral valve repair for Barlow-type or complex bileaflet degenerative disease, evaluating overall survival, freedom from mitral regurgitation 2+ or greater, need for reoperation, and New York Heart Associaton class. From 2008 to 2016, 140 consecutive patients with Barlow-type degenerative bileaflet mitral valve disease underwent video-assisted minimally invasive right anterolateral thoracotomy repair at a single institution. In all cases, the repair was based on the Re-Lock maneuver. Patients were classified according to the need for anterior intervention. Group 1 included patients receiving Re-Lock only (n = 33), in whom anterior billowing or mild prolapse became competent after posterior correction and required no additional repair. Group 2 included patients receiving Re-Lock + anterior expanded polytetrafluoroethylene neochordae (n = 107), in whom true anterior prolapse or flail warranted targeted neochordal implantation. Follow-up was completed through scheduled clinical and echocardiographic evaluations, with a median duration of 10.2 years. Technical success with freedom of mitral regurgitation (mild or less on intraoperative transesophageal echocardiography) was 99.3%, with no 30-day mortality. At 10 years, overall survival was 95.7%. Freedom from mitral regurgitation 2+ or greater was 91.2%, and freedom from reoperation was 96.4%. Postoperative New York Heart Association class improved in 130 of 140 patients (92.9%) and maintained class I at last follow-up in 122 of 130 survivors (93.8%). No statistically significant difference was observed in outcomes by technique group (log-rank P = .74). A learning curve was evident, with crossclamp time decreasing from 69.7 ± 11.9 to 45.3 ± 10.4 minutes over time. The minimally invasive Re-Lock technique provides safe, reproducible, and effective long-term results for complex bileaflet mitral valve disease, including Barlow's pathology. Re-Lock in bileaflet degenerative MR. A, Prerepair assessment of bileaflet degenerative MR with billowing/pseudoprolapse and annular dilatation. B, Posterior leaflet relocation with “locking” sutures to eliminate excess height and abolish functional pseudoprolapse; sliding annuloplasty as needed for height control. C, Ring sizing and implantation to restore annular geometry and stabilize coaptation. D, Selective anterior ePTFE neochordae when predefined criteria are met, targeting a coaptation length 8 mm or more and durable competence. ePTFE , Expanded polytetrafluoroethylene; MR , mitral regurgitation.

Authors

Institutions

Publication Details

Journal
JTCVS Open
Published
2025-12-05
DOI
https://doi.org/10.1016/j.xjon.2025.101543
Primary Topic
Cardiac Valve Diseases and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Minimally invasive mitral valve repair: Ten-year outcomes of the “Re-Lock technique” for complex bileaflet mitral valve disease

Tommaso Loizzo, Giuseppe Nasso, Ernesto Greco, Raffaele Bonifazi et al.
JTCVS Open
Cardiac Valve Diseases and Treatments
article

Minimally invasive mitral valve repair: Ten-year outcomes of the “Re-Lock technique” for complex bileaflet mitral valve disease

Tommaso Loizzo, Giuseppe Nasso, Ernesto Greco, Raffaele Bonifazi, Giuseppe Speziale
article en

Abstract

The objective was to evaluate the 10-year clinical and echocardiographic outcomes of minimally invasive Re-Lock mitral valve repair for Barlow-type or complex bileaflet degenerative disease, evaluating overall survival, freedom from mitral regurgitation 2+ or greater, need for reoperation, and New York Heart Associaton class. From 2008 to 2016, 140 consecutive patients with Barlow-type degenerative bileaflet mitral valve disease underwent video-assisted minimally invasive right anterolateral thoracotomy repair at a single institution. In all cases, the repair was based on the Re-Lock maneuver. Patients were classified according to the need for anterior intervention. Group 1 included patients receiving Re-Lock only (n = 33), in whom anterior billowing or mild prolapse became competent after posterior correction and required no additional repair. Group 2 included patients receiving Re-Lock + anterior expanded polytetrafluoroethylene neochordae (n = 107), in whom true anterior prolapse or flail warranted targeted neochordal implantation. Follow-up was completed through scheduled clinical and echocardiographic evaluations, with a median duration of 10.2 years. Technical success with freedom of mitral regurgitation (mild or less on intraoperative transesophageal echocardiography) was 99.3%, with no 30-day mortality. At 10 years, overall survival was 95.7%. Freedom from mitral regurgitation 2+ or greater was 91.2%, and freedom from reoperation was 96.4%. Postoperative New York Heart Association class improved in 130 of 140 patients (92.9%) and maintained class I at last follow-up in 122 of 130 survivors (93.8%). No statistically significant difference was observed in outcomes by technique group (log-rank P = .74). A learning curve was evident, with crossclamp time decreasing from 69.7 ± 11.9 to 45.3 ± 10.4 minutes over time. The minimally invasive Re-Lock technique provides safe, reproducible, and effective long-term results for complex bileaflet mitral valve disease, including Barlow's pathology. Re-Lock in bileaflet degenerative MR. A, Prerepair assessment of bileaflet degenerative MR with billowing/pseudoprolapse and annular dilatation. B, Posterior leaflet relocation with “locking” sutures to eliminate excess height and abolish functional pseudoprolapse; sliding annuloplasty as needed for height control. C, Ring sizing and implantation to restore annular geometry and stabilize coaptation. D, Selective anterior ePTFE neochordae when predefined criteria are met, targeting a coaptation length 8 mm or more and durable competence. ePTFE , Expanded polytetrafluoroethylene; MR , mitral regurgitation.

JTCVS OpenVol. 29
Libera Università Maria SS. Assunta (IT), Santa Maria Nuova Hospital (IT), Villa Maria Hospital (UG), European University of Rome (IT)
Openalex Percentile: Top 44%
Cardiac Valve Diseases and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.